Danish pharmaceutical giant Novo Nordisk has lowered its financial expectations for next year. The company announced revised projections alongside its third quarter results.
Novo Nordisk now expects revenue growth of 8-11 percent, down from previous estimates of 8-14 percent. Operating profit growth is projected at 4-7 percent, reduced from 4-10 percent.
The adjustment follows a substantial cost-cutting initiative across the company's operations. Novo Nordisk employs over 60,000 people globally and is Europe's most valuable listed company.
What does this mean for diabetes and weight loss medication supplies? The company produces popular drugs like Ozempic and Wegovy that face ongoing global demand.
This revision suggests even industry leaders face pressure despite blockbuster products. The company must balance research investments with shareholder expectations during economic uncertainty.